02557nas a2200349   4500000000100000008004100001260001300042653001000055653001100065653001100076653001300087653002500100653000900125653002400134653002500158653000900183653001600192653001300208100001300221700001300234700001600247700001200263700001400275700001500289245013600304856005900440300001100499490000700510050003200517520164400549022001402193       2001                            d  c2001 Jun10aAdult10aFemale10aHumans10aLepromin10aLeprosy, lepromatous10aMale10aMycobacterium bovis10aMycobacterium leprae10aSkin10aVaccination10aVaccines1 aWakhlu A1 aGaur S P1 aKaushal G P1 aMisra A1 aAsthana P1 aSircar A R00aResponse of Mycobacterium habana vaccine in patients with lepromatous leprosy and their household contacts. A pilot clinical study.  uhttp://leprev.ilsl.br/pdfs/2001/v72n2/pdf/v72n2a08.pdf  a179-910 v72  aInfolep Library - available3 a<p>Single dose vaccination was carried out with Mycobacterium habana vaccine, 31 lepromatous leprosy cases receiving 1.5 mg (1.5 mg = 6.27 x 10(8) bacilli) and 36 household contacts randomly receiving 1.5, 2.0, 2.5 mg vaccine intradermally. Duration of study was 18 weeks. Vaccination induced lepromin conversion in 100% of lepromatous leprosy cases and lepromin negative household contacts and augmentation of lepromin reactivity in 100% of lepromin positive household contacts, which was stable for the 15 weeks duration of follow-up. The maximum augmentation in lepromin reactivity was obtained with 1.5 mg of vaccine, which is probably the supramaximal dose. Overall, post-vaccination, those without prior BCG vaccination scars showed higher mean values of lepromin augmentation. Local vaccination site changes included induration, ulceration, itching, pain and uncomplicated regional lymphadenopathy, all of which remitted spontaneously by 15 weeks. Systemic side-effects noted were pyrexia, ENL and jaundice, and were seen with no greater frequency than that reported in other vaccine trials. Overall, systemic side-effects were easily controlled and were not accompanied by clinically detectable nerve or ocular damage. The safety profile investigations revealed an increase in the mean values of Hb%, RBC count and PCV in household contacts and of PCV in lepromatous patients, post-vaccination. Alterations in the liver function tests were also observed in patients of lepromatous leprosy. Thus, M. habana vaccine appears to be useful in stimulating specific CMI against M. leprae as evidenced by increased lepromin reactivity.</p>  a0305-7518